WITHDRAWN: Analysis of risk factors associated with unfavorable response to treatments in rifampicin-sensitive pulmonary tuberculosis patients

Author:

Lv Luyi1,Ye Ling1,Lan Jianhua1,Fang Min2,Wang Tao3,Wu Zhiyu3,Wu Shugen3,Lu Weili3,Peng Chunxian3,Lu Tao3

Affiliation:

1. The 2nd clinical medical college of zhejiang Chinese Medical university

2. The People's Hospital of Ke Cheng

3. The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People’s Hospital)

Abstract

Abstract

Background This study aimed to analyze the risk factors influencing the unfavorable responses to treatments in rifampicin-sensitive pulmonary tuberculosis (PTB) patients for the early identification of high-risk patients and timely interventions. Methods Rifampicin-sensitive PTB patients admitted to the Department of Infectious Diseases, Quzhou Hospital Affiliated to Wenzhou Medical University, between January 1, 2020, and December 31, 2021, were included. Univariable and multivariable logistic regression analyses were used to analyze the relevant risk factors, and the predictive value of these risk factors was assessed using the receiver operating characteristic (ROC) curve. Results A total of 731 rifampicin-sensitive PTB patients were included. Multivariable logistic regression analysis showed that male gender (odds ratio [OR] = 2.397, 95% confidence interval [CI] 1.227-4.684), age ≥ 60 years (OR = 3.527, 95% CI 1.675-7.425), concomitant respiratory failure (OR = 3.727, 95% CI 1.163-11.944), elevated C-reactive protein (CRP) (OR = 1.008, 95% CI 1.002-1.013), decreased CD4+/CD8+ ratio (OR = 0.783, 95% CI 0.628-0.976), and low body mass index (BMI) (OR = 0.908, 95% CI 0.829-0.994) were identified as risk factors for failed treatments in rifampicin-sensitive PTB patients (P< 0.05). Male gender (OR = 13.701, 95% CI 1.461-128.481), age ≥ 60 years (OR = 5.684, 95% CI 1.058-30.538), concomitant chronic obstructive pulmonary disease (OR = 3.531, 95% CI 1.163-10.718), hypoalbuminemia (OR = 0.801, 95% CI 0.692-0.928), decreased CD4+/CD8+ ratio (OR = 0.637, 95% CI 0.412-0.984), and low BMI (OR = 0.787, 95% CI 0.643-0.963) were identified as prognostic risk factors for rifampicin-sensitive PTB patients (P < 0.05). The areas under the curve (AUC) for CRP, CD4+/CD8+, and BMI in predicting unfavorable treatment responses were 0.697, 0.576, and 0.632, respectively. The AUCs for serum albumin, CD4+/CD8+, and BMI in predicting mortality in rifampicin-sensitive PTB patients were 0.907, 0.651, and 0.710, respectively. Conclusion Male gender, age ≥ 60 years, concomitant respiratory failure and chronic obstructive pulmonary disease, hypoalbuminemia, elevated CRP, decreased CD4+/CD8+ ratio, and low BMI were identified as risk factors for unfavorable treatment responses in rifampicin-sensitive PTB patients. Specifically, serum albumin alone showed the highest prognostic predictive value among rifampicin-sensitive PTB patients.

Publisher

Research Square Platform LLC

Reference19 articles.

1. Furin J, Cox H, Pai M, Tuberculosis[J]. Lancet. 2019;393(10181):1642–56. 10.1016/S0140-6736(19)30308-3.

2. World Health Organization. Global Tuberculosis Report 2023. WHO; 2023.

3. Chinese Medical Association, Chinese Journal of General Practitioners Editorial Board, Chinese Society of General Practice, et al. Guidelines for the Diagnosis and Treatment of Tuberculosis at Primary Care Level et al. (2018) [J]. Chinese Journal of General Practitioners, 2019, 18(8): 709–717. 10.3760/cma.j.issn.1671-7368.2019.08.002.

4. Poor adult tuberculosis treatment outcome and associated factors in Gibe Woreda, Southern Ethiopia: An institution-based cross-sectional study[J];Mengesha MM;PLOS Glob Public Health 2022

5. Spatial distribution and risk factors of adverse treatment outcomes of tuberculosis in Guizhou, China, 2013–2018[J];Zhou J;Sci Rep

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3